Skip to Main Content

Paper Details

Tipifarnib as a Precision Therapy for <i>HRAS</i>-Mutant Head and Neck Squamous Cell Carcinomas.
Mol Cancer Ther
62
2020
-mutant cells, FTase, HNSCC, HNSCC PDXs, HNSCCs, HRAS, HRAS mutations, HRAS-Mutant Head, HRAS-mutant, HRAS-mutant cells, HRAS-mutant tumors, HRAS-mutant xenografts, MAPK, PDX, RAS isoforms, Tipifarnib, endothelial cells, farnesyl, farnesyltransferase, mutant, oncogene, patient, squamous cell, tipifarnib, tumor, tumor cells, wild-type HRAS, xenograft models
Author NameAffiliation
Mara GilardiMoores Cancer Center, University of California San Diego
Zhiyong WangMoores Cancer Center, University of California San Diego
Yusuke GotoMoores Cancer Center, University of California San Diego
Alfredo A MolinoloMoores Cancer Center, University of California San Diego
Alfredo A MolinoloMoores Cancer Center, University of California San Diego
Jorge Silvio GutkindMoores Cancer Center, University of California San Diego
  • 1 - 6

Datasets

Release 1.2